Abstract 3185
Background
Bone targeting agents (BTA) are prescribed for the prevention of skeletal-related events in patients with bone metastases from solid tumors. The use of BTA varies by region and little is known about use in Asia. This study evaluated the utilization patterns of BTA in patients within Taiwan, Hong Kong, and Korea.
Methods
This retrospective cohort study included patients diagnosed with a solid tumor (breast, prostate, or lung cancer) and with receipt of a BTA (intravenous zoledronate, pamidronate, or denosumab). All records were retrieved from databases including: the Taiwan National Health Insurance Database (NHID) of years 2012-2017, Korea’s NHID of years 2012-2016, and Hong Kong’s Clinical Data Analysis and Reporting System (CDARS) of years 2012-2017. Descriptive analyses were conducted to describe patient characteristics, the rate of BTA use among patients with a solid tumor by year and duration of BTA use in Taiwan, Hong Kong and Korea.
Results
We identified 18,286 (54% male), 2,861 (48% male) and 12,803 (41% male) patients with a solid tumor and BTA receipt in Taiwan, Hong Kong, and Korea, respectively. The mean age at BTA recipient was 64.1 (SD 13.7) in Taiwan, 64.3 (SD 12.8) in Hong Kong, and 61.5 (SD 12.9) in Korea. For patients with BTA use, the predominant tumor type was breast cancer in Taiwan (41%) and Korea (50%), and was lung cancer (53%) in Hong Kong. For the entire study period, the rates of BTA use among solid tumor patients were 8.3% in Taiwan, 5.9% in Hong Kong and 3.1% in Korea. The rates of BTA use increased gradually during study period in each place. In year 2016, the most prevalent BTA used was denosumab (7.7%) in Taiwan and zoledronate in Hong Kong (3.7%) and Korea (1.8%). Denosumab was not available in Korea during the study period. The mean duration of BTA use was 111 (SD 154) days in Taiwan, 110 (SD 148) in Hong Kong and 133 (SD 188) days in Korea.
Conclusions
In this first analysis reporting on treatment patterns for BTA use in Asia, the results suggest variation in BTA use among places and a shorter treatment duration of BTA use in clinical practice compared with guideline recommendations. The study provided fundamental information for subsequent evaluations of how this variation in BTA use may be associated with optimal clinical outcomes in Asia.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Funding
Amgen Asia Holding Limited (Hong Kong).
Disclosure
S.N. Gao: Research grant / Funding (institution): Amgen Asia Holding Limited (Hong Kong). N. Kleinman: Research grant / Funding (institution): Amgen Asia Holding Limited (Hong Kong). J. Lange: Research grant / Funding (institution): Amgen Inc., Thousand Oaks, CA, USA. T.C. Lin: Research grant / Funding (institution): Amgen Inc., Thousand Oaks, CA, USA. All other authors have declared no conflicts of interest.
Resources from the same session
3536 - Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis
Presenter: Mylin Torres
Session: Poster Display session 2
Resources:
Abstract
4022 - Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from the CompLEEment-1 trial
Presenter: Mario Campone
Session: Poster Display session 2
Resources:
Abstract
3599 - Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices
Presenter: Rachel Layman
Session: Poster Display session 2
Resources:
Abstract
901 - Pharmacokinetics (PK), safety, and efficacy of [fam-] trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumors
Presenter: Yung-Jue Bang
Session: Poster Display session 2
Resources:
Abstract
2777 - A Phase 2 study of abemaciclib in patients (pts) with brain metastases (BM) secondary to non-small cell lung cancer (NSCLC) or melanoma (MEL).
Presenter: Solmaz Sahebjam
Session: Poster Display session 2
Resources:
Abstract
3980 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
Presenter: Michelino De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
4024 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase 3b CompLEEment-1 trial
Presenter: Paul Cottu
Session: Poster Display session 2
Resources:
Abstract
2151 - Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract
3994 - Safety and efficacy of Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study.
Presenter: Michele De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
1370 - Interim Results From CompLEEment-1 (A Phase 3b Study of Ribociclib and Letrozole as First-Line Therapy for Advanced Breast Cancer in an Expanded Population): Spanish cohort results
Presenter: Javier Salvador
Session: Poster Display session 2
Resources:
Abstract